“Tier 1 stock exchanges remain the only exchanges to be included in indexes around the world – yet not every exchange is recognized and eligible for inclusion,” noted Jos Schmitt, President, and CEO of NEO. “Today marks a pivotal achievement in NEO’s journey to provide much-needed competition and innovation in the Canadian capital markets landscape. Achieving recognition by FTSE Russell is a validation of NEO as a proven and reputable Canadian mainboard stock exchange. This accreditation enables NEO to offer yet another benefit to capital-raising companies, above and beyond our exceptional client service and support, unique liquidity solutions, and unfettered access to market data.”
MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company announced that effective as of Friday March 19th, 2021, MindMed has been added to the FTSE Global Micro-Cap Index (which represents $1.3 trillion in global market cap) and the FTSE Total-Cap index (which represents $54.7 trillion in global market cap).
J.R. Rahn, Chief Executive Officer of MindMed said, “Being included in mature and credible indexes like the FTSE Total Cap and FTSE Global Micro-Cap is a true honor. As we build MindMed into a pioneering company for the long-term, our entire team looks forward to the potential positive change we can bring to treating mental health and addiction in the years ahead.”